Bio-Rad Laboratories is navigating significant financial hurdles, having reported a $527 million net loss in Q1 2026 amid a tough academic market and external pressures from global conflicts. Although the company projects a modest revenue growth of 0.9% for the current quarter, at $657.36 million, it faces potential constraints due to limited government funding. The recent acquisition of Stilla Technologies aims to bolster its product offerings, yet the company's stock has suffered a 7.24% decline over the past month, raising concerns about its recovery trajectory.
Click a month on the chart to update the report below.
